Replies to post #213587 on Biotech Values

[BottomBounce]

$HTBX Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer http://ir.heatbio.com/press-releases/detail/573

[DewDiligence]

Re: ADXS selloff

ADXS reported FY3Q17 financials yesterday, and the cash burn was high. Moreover, the start of the phase-1 NEO trial is delayed until 1H18 for undisclosed reasons. The HER2 program has been discontinued.

If all that weren't enough, the company still hasn't named a permanent CEO or explained why the previous CEO was fired.

https://www.businesswire.com/news/home/20170911006168/en
https://www.sec.gov/Archives/edgar/data/1100397/000149315217010463/form10q.htm

I'm still long with a small position (#msg-133812472), but I haven't added on the downturn.